We acknowledge that previous studies demonstrated that EOR of IDH-mutant astrocytoma was associated with survival.25–27 mOS for the patients who underwent GTR in this series was longer than that in patients who underwent non-GTR procedures, but the difference was not statistically significant, possibly due to the low number of patients who underwent GTR (48 of the 241 patients) as defined by review of imaging studies by the neuroradiologists and limitations in the length of follow up in this study. This evidence concerns the gene IDH2 and astrocytoma (excluding glioblastoma).